Orticumab Clinical Trials (2026): 2 Studies for Inflammation & Atherosclerotic Coronary Vascular Disease

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: .

2 Orticumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 2 indications (including Inflammation & Atherosclerotic Coronary Vascular Disease) and 317 total planned enrollment. 1 Orticumab clinical trial is actively recruiting at 5 U.S. sites across 5 states. Most recent activity: NCT06927739 (Jun 2027).

Where to Participate: All Orticumab Trial Sites in the U.S. (5 sites across 5 states)

Every actively recruiting Orticumabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

StateFacilityCityTrialMap
CAAbcentra Investigational SiteTorrance90502NCT06927739Map
FLAbcentra Investigational SiteBoca Raton33434NCT06927739Map
INAbcentra Investigational SiteRichmond47374NCT06927739Map
MDAbcentra Investigational SiteBaltimore21215NCT06927739Map
MIAbcentra Investigational SiteMidland48670NCT06927739Map

Orticumab clinical trials at a glance: phase × recruitment status

PhaserecruitingcompletedTotal
P2112

Recruiting Orticumab clinical trials (1)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT IDTitlePhaseIndicationEnrollmentStarted
NCT06927739FORTIFYFocused Orticumab Research for Treating Inflammation in Coronary ArteriesP2Acute Coronary Syndromes240Aug 2025

Orticumab clinical trials by indication

Acute Coronary Syndromes (1)

NCTAcronymPhaseStatusTitle
NCT06927739FORTIFYP2recruitingFocused Orticumab Research for Treating Inflammation in Coronary Arteries

Psoriasis (1)

NCTAcronymPhaseStatusTitle
NCT04776629P2completedA Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors

Orticumab pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

AcronymNCTPhaseStatusIndicationEnrollmentPubMed
FORTIFYNCT06927739P2recruitingAcute Coronary Syndromes240

All Orticumab trials (2)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT IDAcronymTitlePhaseStatusEnrollmentSponsorStarted
NCT06927739FORTIFYFocused Orticumab Research for Treating Inflammation in Coronary ArteriesP2recruiting240AbcentraAug 2025
NCT04776629A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk FactorsP2completed77AbcentraJun 2021

Orticumab clinical trials: frequently asked questions

How many Orticumab clinical trials are there?
2 Orticumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 1 is marked completed.
Are Orticumab clinical trials recruiting in 2026?
Yes — 1 Orticumab trial is actively recruiting in 2026, with 5 U.S. sites across 5 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Orticumab being studied for?
Orticumab is being studied for Inflammation, Atherosclerotic Coronary Vascular Disease, Cardiometabolic Syndrome, Coronary Arterial Disease (CAD), Coronary Artery Disease and 4 more. The trials are grouped by indication on this page.
What phase is Orticumab in?
Orticumab clinical trials span 2 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Orticumab clinical trials?
The lead sponsor across the most Orticumab trials is Abcentra. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Orticumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed .

Related pages on Hipa.ai: